New 4‐phenylpiperazine‐carbodithioate‐N‐phenylacetamide hybrids: Synthesis, in vitro and in silico evaluations against cholinesterase and α‐glucosidase enzymes

A series of novel 4‐phenylpiperazine‐carbodithioate‐N‐phenylacetamide hybrids (6a–n) was designed, synthesized, and evaluated for their in vitro inhibitory activity against the metabolic enzymes, acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and α‐glucosidase. The obtained results showed that most of the synthesized compounds exhibited high to good anti‐AChE and anti‐BChE activity in the range of nanomolar concentrations in comparison to tacrine as a positive control. Molecular modeling of the most potent compounds 6e and 6i demonstrated that these compounds interacted with important residues of the AChE and BChE active sites. Moreover, all the newly synthesized compounds 6a–n had significant Ki values against α‐glucosidase when compared with the positive control acarbose. Representatively, N‐2‐fluorophenylacetamide derivative 6l, with a Ki value of 0.98 nM as the most potent compound, was 126 times more potent than acarbose with a Ki value of 123.70 nM. This compound also fitted in the α‐glucosidase active site and interacted with key residues. An in silico study of the druglikeness/absorption, distribution, metabolism, and excretion (ADME)/toxicity profile of the selected compounds 6e, 6i, and 6l predicts that these compounds are drug‐like and have the appropriate properties in terms of ADME and toxicity. Novel 4‐phenylpiperazine‐carbodithioate‐N‐phenylacetamide hybrids (6a–n) were designed, synthesized, and evaluated for their in vitro inhibitory activity against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and α‐glucosidase. Most of the synthesized compounds exhibited high to good anti‐AChE and anti‐BChE activity compared to tacrine as a positive control. Compounds 6e and 6i, with good druglikeness and toxicity profile, interact with important residues of the AChE and BChE active sites.